Lucid Diagnostics (LUCD) Registration Filing summary

Company overview and business model

• Commercial-stage medical diagnostics technology company focused on patients with GERD at risk for esophageal precancer and cancer, especially EAC.

• Flagship products are the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, offering noninvasive early detection of esophageal precancer.

• Technology is based on licensed patents from Case Western Reserve University and targets early detection in at-risk GERD patients.

• Subsidiary of PAVmed, which controls a majority of voting power.

Financial performance and metrics

• Raised $44.3 million in March 2024 and $11.6 million in May 2024 through private placements of Series B and Series B-1 Convertible Preferred Stock.

• Has incurred operating losses since inception and may not achieve profitability; substantial doubt exists about ability to continue as a going concern.

• Significant dilution expected due to convertible securities and additional capital needs.

Use of proceeds and capital allocation

• Will not receive proceeds from the sale of shares by selling stockholders; proceeds from prior private placements used for general corporate purposes.